p16 promoter hypermethylation is associated with increased breast cancer risk

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 904-908

  Wang, Li ^a   Tang, Lin ^a   Xie, Ruilian ^a   Nie, Weiwei ^a   Chen, Longbang ^a   Guan, Xiaoxiang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Breast cancer; Estrogen receptor; Meta analysis; p16 hypermethylation; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P16;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER TISSUE; CARCINOGENESIS; CASE CONTROL STUDY; DNA METHYLATION; HUMAN; META ANALYSIS (TOPIC); PROTEIN ANALYSIS;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DATABASES, FACTUAL; DNA METHYLATION; FEMALE; HUMANS; ODDS RATIO; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84865166400     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1001     Document Type: Article

References (30)

1. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 61:409-418, 2011.
2. Tao MH, Shields PG, Nie J, et al: DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 114: 559-568, 2009.
3. Holst CR, Nuovo GJ, Esteller M, et al: Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63: 1596-1601, 2003. (Pubitemid 36373649)
4. Tlsty TD, Crawford YG, Holst CR, et al: Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 9: 263-274, 2004.
5. Wajed SA, Laird PW and DeMeester TR: DNA methylation: An alternative pathway to cancer. Annals Surg 234: 10-20, 2001. (Pubitemid 32619329)
6. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis - epigenetics joins genetics. Trends Genet 16: 168-174, 2000. (Pubitemid 30169152)
7. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001. (Pubitemid 32695003)
8. Di Vinci A, Perdelli L, Banelli B, et al: p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114: 414-421, 2005. (Pubitemid 40279962)
9. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B and Kreipe H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160: 605-612, 2002. (Pubitemid 34160338)
10. Cavusoglu AC, Sevinc AI, Saydam S, et al: Promoter methylation and expression changes of CDH1 and P16 genes in invasive breast cancer and adjacent normal breast tissue. Neoplasma 57: 465-472, 2010.
11. Jing F, Jun L, Yong Z, et al: Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology 75: 60-66, 2008.
12. Jing F, Yuping W, Yong C, et al: CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol 31: 321-331, 2010.
13. Raish M, Dhillon VS, Ahmad A, et al: Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol 2: 264-270, 2009.
14. Vallian S, Sedaghat M, Nassiri I and Frazmand A: Methylation status of p16 (INK4A) tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol 135: 991-996, 2009.
15. Van Zee KJ, Calvano JE and Bisogna M: Hypomethylation and increased gene expression of p16(INK4a) in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 16: 2723-2727, 1998. (Pubitemid 28279337)
16. Woodcock DM, Linsenmeyer ME, Doherty JP and Warren WD: DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer 79: 251-256, 1999. (Pubitemid 29002293)
17. Moher D, Liberati A, Tetzlaff J, Altman DG and Grp P: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Reprinted from Annals of Internal Medicine). Physical Therapy 89: 873-880, 2009.
18. Bero L and Rennie D: The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health-care. JAMA 274: 1935-1938, 1995. (Pubitemid 26003064)
19. Higgins JPT, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003. (Pubitemid 37088507)
20. Jing F, Zhang J, Tao J, et al: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3 sigma in serum of sporadic breast cancer patients. Onkologie 30: 14-19, 2007. (Pubitemid 46175615)
21. Li SY, Rong MN and Iacopetta B: DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237: 272-280, 2006.
22. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
23. Yang X, Yan L and Davidson NE: DNA methylation in breast cancer. Endocr Relat Cancer 8: 115-127, 2001. (Pubitemid 32641353)
24. Szyf M, Pakneshan P and Rabbani SA: DNA methylation and breast cancer. Biochem Pharmacol 68: 1187-1197, 2004. (Pubitemid 39094284)
25. Rocco JW and Sidransky D: p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264: 42-55, 2001. (Pubitemid 32989080)
26. Sherr CJ and McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2: 103-112, 2002. (Pubitemid 41039110)
27. McDermott KM, Zhang JM, Holst CR, Kozakiewicz BK, Singla V and Tlsty TD: p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 4: 350-365, 2006.
28. Bender CM, Pao MM and Jones PA: Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101, 1998. (Pubitemid 28027723)
29. Zhang B, Huang T, Liu K, Chen J and Wang G: Effects of 5-Aza-CdR on cell proliferation of breast cancer cell line MDA-MB-435S and expression of maspin gene. J Huazhong Univ of Sci Technology Med Sci 27: 543-546, 2007.
30. David GL, Yegnasubramanian S, Kumar A, et al: MDR1 promoter hypermethylation in MCF7 human breast cancer cells - Changes in chromatin structure induced by treatment with 5-aza-cytidine. Cancer Biol Ther 3: 540-548, 2004. (Pubitemid 41351125)